Sign in
IMA Stock Price, Chart, Stats & News
ImageneBio Inc
Save
ImageneBio Inc (IMA) does not currently pay a dividend.
53.24M
Market cap
–
Current P/E
–
Forward P/E
IMA chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 0.71% |
ROA | -28.16% |
ROE | -33.97% |
D/E | 0.08x |
Interest coverage ratio | -569.19x |
IMA valuation
P/E | – |
P/S | – |
P/B | 0.42x |
P/CF | -1.17x |
P/FCF | -1.17x |
P/OCF | -1.17x |
PEG | 0.10x |
EV multiple | -1.61x |
About
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025.
Similar securities
Based on sector and market capitalization
Report issue